2023
Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm
Volpe V, Luskin M, Stahl M, Lindsley C, DeAngelo D. Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm. Blood 2023, 142: 6400. DOI: 10.1182/blood-2023-184587.Peer-Reviewed Original ResearchAcute myeloid leukemiaTransformation to acute myeloid leukemiaMolecular signatures of patientsSM-AHNOverall survivalRAS pathway mutationsCo-mutationsMast cellsSystemic mastocytosisMyeloid neoplasmsHematologic neoplasmsMyeloid leukemiaFLT3-ITDAccumulation of neoplastic mast cellsPathway mutationsTransition to acute myeloid leukemiaProgression to acute myeloid leukemiaAcute myeloid leukemia transformationAdvanced myeloid neoplasmsPrognosticate overall survivalEstimate overall survivalAdvanced systemic mastocytosisAML driver mutationsNext generation sequencingMast cell activation
2021
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
Malone R, Tisdall P, Fremont-Smith P, Liu Y, Huang X, White K, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker C, Wang G, Pottel J, Blair R, Roy C, Smith N, Hall J, Tomera K, Shapiro G, Mittermaier A, Kruse A, García-Sastre A, Roth B, Glasspool-Malone J, Ricke D. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers In Pharmacology 2021, 12: 633680. PMID: 33833683, PMCID: PMC8021898, DOI: 10.3389/fphar.2021.633680.Peer-Reviewed Original ResearchSARS-CoV-2 infectionCOVID-19 diseaseSARS-CoV-2Mast cell activationClinical COVID-19Acute viral diseaseMechanism of actionSymptoms of COVID-19Dose selectionClinical dataTreatment strategiesTreatment of COVID-19 diseaseHistamine releaseCell activationWell-characterized drugsCOVID-19 symptomsClinical COVID-19 diseaseOral formFamotidineMedical countermeasuresDiseaseInpatient treatmentCOVID-19InfectionSymptomsInflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target
Chen E, Chuang LS, Giri M, Villaverde N, Hsu NY, Sabic K, Joshowitz S, Gettler K, Nayar S, Chai Z, Alter IL, Chasteau CC, Korie UM, Dzedzik S, Thin TH, Jain A, Moscati A, Bongers G, Duerr RH, Silverberg MS, Brant SR, Rioux JD, Peter I, Schumm LP, Haritunians T, McGovern DP, Itan Y, Cho JH. Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target. Gastroenterology 2021, 160: 1709-1724. PMID: 33421512, PMCID: PMC8494017, DOI: 10.1053/j.gastro.2020.12.076.Peer-Reviewed Original ResearchMeSH KeywordsAdrenomedullinAnimalsbeta-Arrestin 2Case-Control StudiesCell DegranulationCHO CellsColitis, UlcerativeColonCricetulusExtracellular Signal-Regulated MAP KinasesGenetic VariationHumansInositol PhosphatesLigandsMast CellsNerve Tissue ProteinsPhosphorylationReceptors, G-Protein-CoupledReceptors, NeuropeptideConceptsExtracellular signal-regulated kinaseSignal-regulated kinaseRNA sequencingArrestin recruitmentChinese hamster ovarySingle-cell RNA sequencingNew therapeutic targetsBulk RNA sequencingMast cell gene expressionCell gene expressionHuman ulcerative colitisKey upstream regulatorUlcerative colitisMast cell activationIP-1 accumulationSingle nucleotide polymorphismsTherapeutic targetCell activationCell-specific mediatorsUpstream regulatorGene expressionGenotype-dependent effectsG proteinsMast cellsIgE-independent mast cell activation
2020
Mast cell activation in the systemic sclerosis esophagus
Tom K, Mehta BK, Hoffmann A, Aren K, Carns M, Lee J, Martyanov V, Popovich D, Kosarek N, Wood T, Brenner D, Carlson DA, Ostilla L, Willcocks E, Bryce P, Wechsler JB, Whitfield ML, Hinchcliff M. Mast cell activation in the systemic sclerosis esophagus. Journal Of Scleroderma And Related Disorders 2020, 6: 77-86. PMID: 34179507, PMCID: PMC8225255, DOI: 10.1177/2397198320941322.Peer-Reviewed Original ResearchMast cell numbersSSc patientsCell-directed therapiesSystemic sclerosisEsophageal biopsiesClinical parametersHealthy participantsCell numberNormal-like subsetsMast cell densityCell-targeted therapiesMast cell markersUseful therapeutic approachMast cell activationMast cell quantityRelevant clinical parametersMolecular classification systemEoE patientsEsophageal symptomsEosinophilic esophagitisUpper esophagusSkin biopsiesEntire esophagusMast cellsTherapeutic approaches
2012
Syntaxin 11 is required for NK and CD8+ T‐cell cytotoxicity and neutrophil degranulation
D'Orlando O, Zhao F, Kasper B, Orinska Z, Müller J, Hermans‐Borgmeyer I, Griffiths G, Stadt U, Bulfone‐Paus S. Syntaxin 11 is required for NK and CD8+ T‐cell cytotoxicity and neutrophil degranulation. European Journal Of Immunology 2012, 43: 194-208. PMID: 23042080, PMCID: PMC5405866, DOI: 10.1002/eji.201142343.Peer-Reviewed Original ResearchConceptsVesicular traffickingSyntaxin-11NK cellsLymphocyte cytotoxicityT cellsIFN-gActivated CD8(+) T cellsCD8+ T cell cytotoxicityCD8(+) T cellsLevels of IFN-gT cell cytotoxicityImmune cell populationsMacrophage phagocytic functionMast cell activationDefective phenotypesImmune cellsSTX11 mutationsAntigen presentationCytokine productionCytokine secretionImpaired degranulationSTX11Cell activationPhagocytic functionFunctional reconstitution
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply